AbbVie makes psychedelic play with $2bn Gilgamesh collaboration

The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.

May 15, 2024 - 04:00

AbbVie makes psychedelic play with $2bn Gilgamesh collaboration

The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.

Read the original article

Tags:

Previous Article

Walden Biosciences teams up with Primula for kidney disease study

Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Amgen showcases exciting potential in the obesity space at JPM24

Amgen showcases exciting potential in the obesity space...

Jan 15, 2024

GSK’s results tease survival benefit trend with Jemperli for endometrial cancer

GSK’s results tease survival benefit trend with Jemperl...

Mar 29, 2023

Banning WuXi is more complicated than it might sound

Banning WuXi is more complicated than it might sound

Mar 8, 2024